A. Park

An effective mouse model for adoptive cancer immunotherapy targeting neoantigens.

N. Restifo, Zhiya Yu, K. Hanada, 2019, JCI insight.

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

L. Horvath, J. Powderly, L. Seitz, 2019, Journal of Clinical Oncology.